https://orcid.org/0000-0002-8014-7103
References
- Yanamandra U, Deo P, Sahu KK, et al. Clinicopathological profile of myelomatous pleural effusion: single-center real-world experience and review of literature. Clin Lymphoma Myeloma Leuk. 2019;19:183–189.e1. doi:10.1016/j.clml.2018.12.003
- Kintzer JS, Rosenow EC, Kyle RA. Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med. 1978;138:727–730. doi:10.1001/archinte.1978.03630290039015
- Cho YU, Chi HS, Park CJ, Jang S, Seo EJ, Suh C. Myelomatous pleural effusion: a case series in a single institution and literature review. Korean J Lab Med. 2011;31:225–230.
- Zhong Y, Zhang J, Wang H. Myelomatous pleural effusion involvement in 23 patients with multiple myeloma: a single-center clinical analysis. Thorac Cancer. 2015;6:359–362. doi:10.1111/1759-7714.12220
- Makino S, Yamahara S, Nagake Y, Kamura J. Bence-Jones myeloma with pleural effusion: response to alpha-interferon and combined chemotherapy. Int Med. 1992;31:617–621. doi:10.2169/internalmedicine.31.617
- Villena Garrido V, Cases Viedma E, Fernández Villar A, et al. Recommendations of diagnosis and treatment of pleural effusion. Update. Arch Bronconeumol. 2014;50:235–249. doi:10.1016/j.arbr.2014.04.007
- Aoe K, Hiraki A, Murakami T, et al. Relative abundance and patterns of correlation among six cytokines in pleural fluid measured by cytometric bead array, Int. J Mol Med. 2003;12(2):193–198.
- Imai K, Kotani T, Tsuda H, Kobayashi T, Ushida T, Moriyama Y. Determination of the cytokine levels in fetal pleural effusion and their association with fetal/neonatal findings. Cytokine. 2020;127:154945. doi:10.1016/j.cyto.2019.154945
- Han L, Jiang Q, Yao W, Fu T, Zeng Q. Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients. BMC Cancer. 2018;18:725. doi:10.1186/s12885-018-4581-5
- Lindner S, Krönke J. The molecular mechanism of thalidomide analogs in hematologic malignancies. J Mol Med. 2016;94:1327–1334. doi:10.1007/s00109-016-1450-z
- Rosiñol L, Cibeira MT, Bladé J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89:832–836.
- Wu P, Davies F, Boyd K, et al. The impact of extramedullary disease at presentation in the outcome of myeloma. Leuk Lymphoma. 2009;50:230–235. doi:10.1080/10428190802657751
- Richardson PG, Blood E, Mitsiades CS, et al. A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458–3464. doi:10.1182/blood-2006-04-015909
- Kumar S, Flinn IW, Richardson PG, et al. Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multicenter, randomized, phase 2 EVOLUTION study. Blood. 2006;116:621(abstr 621).
- Hagihara M, Ide S, Ohara S, Uchida T, Inoue M, Hua J. omalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary. lesions Rinsho Ketsueki. 2020;61(1):20–26.